|
1）日本アイソトープ協会 医学・薬学部会全国核医学診療実態調査専門委員会．第7回全国核医学診療実態調査報告書．Radioisotopes. 2013; 62: 545-608
|
|
|
|
2）日本核医学会PET核医学委員会，日本アイソトープ協会医学・薬学部会．PET検査件数に関するアンケート調査報告（第10報）．Isotope News. 2013; 712: 38-42
|
|
|
|
|
|
3）Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001; 15: 471-86
|
|
|
|
|
4）Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998; 39: 1016-20
|
|
|
|
|
|
5）Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology. 2000; 216: 117-21
|
|
|
|
|
|
6）日本肺癌学会，編．肺癌診療ガイドライン 2014年版（第3版）．東京：金原出版；2014
|
|
|
|
|
|
7）日本医学放射線学会，日本放射線科専門医会・医会，編．画像診断ガイドライン 2013年版．東京：金原出版；2013
|
|
|
|
|
|
8）Lv YL, Yuan DM, Wang K, et al. Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011; 6: 1350-8
|
|
|
|
|
|
9）Bury T, Barreto A, Daenen F, et al. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med. 1998; 25: 1244-7
|
|
|
|
|
|
10）NCCN Guidelines Version 2. 2013. Non-Small Cell Lung Cancer. National Comprehensive Cancer Network, Washington, PA. http://www.nccn.org/
|
|
|
|
|
|
11）Sunaga N, Oriuchi N, Kaira K, et al. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 2008; 59: 203-10
|
|
|
|
|
|
12）Bengtsson T, Hicks RJ, Peterson A, et al. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012; 53: 530-7
|
|
|
|
|
|
13）Kobe C, Scheffler M, Holstein A, et al. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib. Eur J Nucl Med Mol Imaging. 2012; 39: 1117-27
|
|
|
|
|
|
14）Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2003; 21: 1285-92
|
|
|
|
|
|
15）Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-86
|
|
|
|
|
|
16）Roberts KB, Manus MP, Hicks RJ, et al. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer. 2005; 47: 49-57
|
|
|
|
|